<A href="http://www.ccheart.com.cn/supersite/batch.download.php?aid=478" target=_blank><IMG src="http://www.ccheart.com.cn/supersite/attachments/2008/04/18884_200804091116041.jpg" border=0></A>

<A href="http://www.ccheart.com.cn/supersite/batch.download.php?aid=479" target=_blank><IMG src="http://www.ccheart.com.cn/supersite/attachments/2008/04/18884_200804091116291.jpg" border=0></A>

<H2>Iodixanol vs Iopromide Study Abstract Presented at American College of Cardiology 2008</H2> <DIV class=t_msgfont id=postmessage_23406> <P>&nbsp;</P> <P>Tuesday April 1, 5:28 pm ET <BR></P> <P>WAUWATOSA, Wis.--(BUSINESS WIRE)--An abstract of a first-ever 208-person study comparing the renal safety, occurrence of cardiovascular adverse events and diagnostic image quality of the isosmolar contrast media (CM) iodixanol and the low-osmolar CM iopromide in patients with chronic kidney disease (CKD) undergoing coronary angiography with or without percutaneous coronary intervention (<SPAN class=t_tag onclick=tagshow(event) href="tag.php?name=PCI">PCI</SPAN>), was available at this week’s ACC Exposition at McCormick Place.</P> <P>&nbsp;</P> <P>The prospective, randomized, double-blind, single-center study is authored by Bin Nie, M.D. and colleagues from Beijing Anzhen Hospital, Beijing, People’s Republic of China.</P> <P>&nbsp;</P> <P>The preliminary conclusion of the study indicates that iso-osmolar CM iodixanol appears to be associated with a significantly lower incidence of Contrast Induced Nephropathy (CIN) and composite cardiovascular events compared with the low-osmolar CM iopromide in patients with CKD undergoing coronary angiography with or without PCI. Additional findings included the image quality of the two agents does not differ. The findings support the class 1A recommendation from the 2007 AHA/ACC guidelines for the management of patients with Unstable-Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) and the AHA/ACC/SCAI 2007 Update of the Guidelines for PCI, recommending the use of isosmolar contrast in patients with CKD who undergo coronary arteriography.</P> <P>&nbsp;</P> <P>ABOUT VISIPAQUE, SELECT SAFETY INFORMATION: </P> <P>&nbsp;</P> <P>In the U.S., Visipaque&#8482; (iodixanol) Injection Nonionic Isosmolar VISIPAQUE IS NOT FOR INTRATHECAL USE. All nonionic, iodinated contrast media currently available inhibit blood coagulation, in vitro, less than ionic contrast media. Clotting has been reported when blood remains in contact with syringes containing nonionic contrast media. Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Caution must be exercised in patients with severely impaired renal function, combined renal and hepatic disease, combined renal and cardiac disease, severe thyrotoxicosis, myelomatosis, or anuria, particularly when large doses are administered.</P> <P>&nbsp;</P> <P>Before administering this product please see the product’s full prescribing information located at <A href="http://www.gehealthcare.com/">www.gehealthcare.com</A>. Because indications vary, consult your country-specific prescribing information.</P> <P>&nbsp;</P> <P>source：GE healthcare</P></DIV>

<A href="http://www.ccheart.com.cn/supersite/batch.download.php?aid=473" target=_blank><IMG src="http://www.ccheart.com.cn/supersite/attachments/2008/04/18884_200804091104031.jpg" border=0></A>

<A href="http://www.ccheart.com.cn/supersite/batch.download.php?aid=475" target=_blank><IMG src="http://www.ccheart.com.cn/supersite/attachments/2008/04/18884_200804091113281.jpg" border=0></A>